Performance of a 31-gene expression profile test in cutaneous melanomas of the head and neck

Brian R. Gastman; Jonathan S. Zager; Jane L. Messina; Robert W. Cook; Kyle R. Covington; Brooke Middlebrook; Pedram Gerami; Jeffrey D. Wayne; Sancy Leachman; John T. Vetto

doi:10.1002/hed.25473

Performance of a 31-gene expression profile test in cutaneous melanomas of the head and neck

Brian R. Gastman^*, Jonathan S. Zager, Jane L. Messina, Robert W. Cook, Kyle R. Covington, Brooke Middlebrook, Pedram Gerami, Jeffrey D. Wayne, Sancy Leachman, John T. Vetto

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

Background: We report the performance of a gene expression profile test to classify the recurrence risk of cutaneous melanoma tumors of the head and neck as low-risk Class 1 or high-risk Class 2. Methods: Of note, 157 primary head and neck cutaneous melanoma tumors were identified. Survival analyses were performed using Kaplan-Meier and Cox methods. Results: Gene expression profile class and node status stratified tumors into significantly different 5-year survival groups by Kaplan-Meier method (P <.0001 for all end points), and both were independent predictors of recurrence in multivariate analysis. Overall, 74% of distant metastases and 88% of melanoma-specific deaths had Class 2 risk. Conclusion: The gene expression profile test identifies cases at increased risk for metastasis and death independent of a clinically or pathologically negative nodal status, suggesting that incorporation of this molecular tool could improve clinical management of patients with head and neck cutaneous melanoma, especially in those with a negative sentinel lymph node biopsy.

Original language	English (US)
Pages (from-to)	871-879
Number of pages	9
Journal	Head and Neck
Volume	41
Issue number	4
DOIs	https://doi.org/10.1002/hed.25473
State	Published - Apr 2019

Funding

The authors wish to thank the following centers for their contributions to the study: Dr. Laura Ferris, University of Pittsburgh Medical Center, Dr. Stephen Lyle, University of Massachusetts Medical School, Dr. Daniel Rosen, Baylor College of Medicine, Dr. Gilchrist Jackson, Kelsey-Seybold Clinic, Dr. Anthony Greisinger, Kelsey Research Foundation, Drs. David Lawson, Maria Russell, and Keith Delman, Winship Cancer Institute of Emory University, Dr. Lewis Kaminester, Dermatology Palm Beach, Dr. Lee Cranmer, University of Arizona Cancer Center, Dr. Rene Gonzalez, University of Colorado Cancer Center, and Dr. Martin Fleming, The University of Tennessee Health Science Center. This study was sponsored by Castle Biosciences, Inc. which provided funding for tissue and clinical data retrieval to contributing centers.

Keywords

cutaneous melanoma
gene expression profiling
metastasis
prognosis
staging

ASJC Scopus subject areas

Otorhinolaryngology

Access to Document

10.1002/hed.25473

Cite this

@article{ffca90999e90405a93b21d2bdb7e57f0,

title = "Performance of a 31-gene expression profile test in cutaneous melanomas of the head and neck",

abstract = "Background: We report the performance of a gene expression profile test to classify the recurrence risk of cutaneous melanoma tumors of the head and neck as low-risk Class 1 or high-risk Class 2. Methods: Of note, 157 primary head and neck cutaneous melanoma tumors were identified. Survival analyses were performed using Kaplan-Meier and Cox methods. Results: Gene expression profile class and node status stratified tumors into significantly different 5-year survival groups by Kaplan-Meier method (P <.0001 for all end points), and both were independent predictors of recurrence in multivariate analysis. Overall, 74% of distant metastases and 88% of melanoma-specific deaths had Class 2 risk. Conclusion: The gene expression profile test identifies cases at increased risk for metastasis and death independent of a clinically or pathologically negative nodal status, suggesting that incorporation of this molecular tool could improve clinical management of patients with head and neck cutaneous melanoma, especially in those with a negative sentinel lymph node biopsy.",

keywords = "cutaneous melanoma, gene expression profiling, metastasis, prognosis, staging",

author = "Gastman, {Brian R.} and Zager, {Jonathan S.} and Messina, {Jane L.} and Cook, {Robert W.} and Covington, {Kyle R.} and Brooke Middlebrook and Pedram Gerami and Wayne, {Jeffrey D.} and Sancy Leachman and Vetto, {John T.}",

note = "Publisher Copyright: {\textcopyright} 2019 Wiley Periodicals, Inc.",

year = "2019",

month = apr,

doi = "10.1002/hed.25473",

language = "English (US)",

volume = "41",

pages = "871--879",

journal = "Head and Neck",

issn = "1043-3074",

publisher = "John Wiley & Sons Inc.",

number = "4",

}

TY - JOUR

T1 - Performance of a 31-gene expression profile test in cutaneous melanomas of the head and neck

AU - Gastman, Brian R.

AU - Zager, Jonathan S.

AU - Messina, Jane L.

AU - Cook, Robert W.

AU - Covington, Kyle R.

AU - Middlebrook, Brooke

AU - Gerami, Pedram

AU - Wayne, Jeffrey D.

AU - Leachman, Sancy

AU - Vetto, John T.

PY - 2019/4

Y1 - 2019/4

N2 - Background: We report the performance of a gene expression profile test to classify the recurrence risk of cutaneous melanoma tumors of the head and neck as low-risk Class 1 or high-risk Class 2. Methods: Of note, 157 primary head and neck cutaneous melanoma tumors were identified. Survival analyses were performed using Kaplan-Meier and Cox methods. Results: Gene expression profile class and node status stratified tumors into significantly different 5-year survival groups by Kaplan-Meier method (P <.0001 for all end points), and both were independent predictors of recurrence in multivariate analysis. Overall, 74% of distant metastases and 88% of melanoma-specific deaths had Class 2 risk. Conclusion: The gene expression profile test identifies cases at increased risk for metastasis and death independent of a clinically or pathologically negative nodal status, suggesting that incorporation of this molecular tool could improve clinical management of patients with head and neck cutaneous melanoma, especially in those with a negative sentinel lymph node biopsy.

AB - Background: We report the performance of a gene expression profile test to classify the recurrence risk of cutaneous melanoma tumors of the head and neck as low-risk Class 1 or high-risk Class 2. Methods: Of note, 157 primary head and neck cutaneous melanoma tumors were identified. Survival analyses were performed using Kaplan-Meier and Cox methods. Results: Gene expression profile class and node status stratified tumors into significantly different 5-year survival groups by Kaplan-Meier method (P <.0001 for all end points), and both were independent predictors of recurrence in multivariate analysis. Overall, 74% of distant metastases and 88% of melanoma-specific deaths had Class 2 risk. Conclusion: The gene expression profile test identifies cases at increased risk for metastasis and death independent of a clinically or pathologically negative nodal status, suggesting that incorporation of this molecular tool could improve clinical management of patients with head and neck cutaneous melanoma, especially in those with a negative sentinel lymph node biopsy.

KW - cutaneous melanoma

KW - gene expression profiling

KW - metastasis

KW - prognosis

KW - staging

UR - http://www.scopus.com/inward/record.url?scp=85060795056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060795056&partnerID=8YFLogxK

U2 - 10.1002/hed.25473

DO - 10.1002/hed.25473

M3 - Article

C2 - 30694001

AN - SCOPUS:85060795056

SN - 1043-3074

VL - 41

SP - 871

EP - 879

JO - Head and Neck

JF - Head and Neck

IS - 4

ER -

Performance of a 31-gene expression profile test in cutaneous melanomas of the head and neck

Abstract

Funding

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this